Safety and Tolerability of PQ912 in Subjects With Early Alzheimer's Disease

NCT02389413 | Completed Phase 2 DMC

• 2 other identifiers: PBD010712014-001967-11
• Study Type: interventional
• Target: 120
• Locations: 7 countries
• Sites: 23

Brief Summary

The aim of this study is to evaluate the safety, tolerability and preliminary efficacy of PQ912 in subjects with Mild Cognitive Impairment (MCI) due to Alzheimers Disease (AD) or mild dementia due to AD.

Conditions

Alzheimer's Disease

Keywords

PQ912; Glutaminy Cyclase (QC); QC - Inhibitor

Outcome Measures

Primary Outcomes (1)

• Frequency of adverse events and serious adverse events (the study is a Phase II safety trial)

  12 weeks

Secondary Outcomes (4)

• Exploratory clinical measures (measured by a questionnaire)

  12 weeks

• Change from baseline of a panel of concept and AD-related biomarkers in Cerebrospinal fluid (CSF) (measured by Analysis of several biochemical assays)

  12 weeks

• Change from baseline in brain functional connectivity (measured by Magnetic Resonance Imaging (MRI) analysis)

  12 weeks

• Change from baseline in functional connectivity and network Analysis in electroencephalography (EEG)

  12 weeks

Study Arms (2)

PQ912 oral

EXPERIMENTAL

PQ912 will be administered orally twice daily for 12 weeks.

Drug: PQ912 oral

Placebo

PLACEBO COMPARATOR

Placebo will be administered orally twice daily for 12 weeks.

Other: Placebo

Interventions

PQ912 oral DRUG

PQ912 oral

Placebo OTHER

Placebo

Eligibility Criteria

• Age: 50 Years - 89 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Signed and dated written informed consent
• Male or surgically sterile or postmenopausal female aged ≥ 50 to ≤ 89 years. Male subjects with childbearing potential partners are willing to and should use condoms during treatment and until 28 days of the last dose of study medication.
• Diagnosis of MCI due to AD or mild dementia due to AD with amnestic presentation, according to AA-NIA (Alzheimer's Association (AA) and the National Institute on (Aging NIA) criteria \[Albert et al 2011; McKhann et al 2011\]
• Mini-Mental State Examination (MMSE) score of 21 to 30 inclusive at screening
• A positive AD signature showing one of the following (either a, b, c, OR d):
• Screening CSF sample with an A-beta 42 concentration of less than 638 ng/L AND total tau \>375 ng/L, as assessed by central laboratory.
• Screening CSF sample with an A-beta 42 concentration of less than 638 ng/L AND p-tau \> 52 ng/L, as assessed by central laboratory.
• Tau/A-beta ratio \> 0.52, as assessed by central laboratory.
• A positive amyloid PET if available prior to screening.
• Treatment naïve, this means not having received any prior established specific treatment for MCI due to AD or mild dementia due to AD including no (prior) use of an acetylcholinesterase inhibitor or memantine. A maximum of two months of prior cumulative treatment with an acetylcholinesterase inhibitor or memantine is allowed if the acetylcholinesterase inhibitor or memantine was discontinued due to intolerance, and if this was done at least two months prior to baseline. Use of Souvenaid will be allowed if Souvenaid was discontinued at least twomonths prior to baseline, or if the subject is on stable dose for at least six months prior to baseline and is willing to continue during the study on the same dose and frequency.
• Outpatient with study partner capable of accompanying the subject on all clinic visits. In accordance to Swedish regulations availability of study partner is not applicable for Sweden.

You may not qualify if:

• Significant neurologic disease, other than AD, that may affect cognition.
• Atypical clinical presentations of MCI due to AD or mild dementia due to AD, such as the visual variant of AD (including posterior cortical atrophy) or the language variant (including logopenic aphasia).
• Concomitant disorders:
• Severe hepatic (Child-Pugh C) and/or kidney failure (creatinine clearance (estimated Glomerular Filtration Rate - eGFR) ≤ 30 ml/min/1.73m2) and/or serum creatinine above 1.5 fold of Upper Limit Normal (ULN) and/or Alanine-Amino Transferase (AST) or Asparagine-Amino Transferase (ALT) above 3 fold ULN at baseline.
• History of or screening visit brain MRI scan indicative of any other significant abnormality.
• Current presence of a clinically important major psychiatric disorder (e.g. major depressive disorder) as defined by DSM-5 criteria, or symptom(s) (e.g. hallucinations) that could affect the subject's ability to complete the study.
• Current clinically important systemic illness that is likely to result in clinically relevant deterioration of the subject's condition or might affect the subject's safety during the study.
• Other clinically important diseases or conditions or abnormalities of vital signs, physical examination, neurologic examination, laboratory results, or electrocardiogram (ECG) examination (e.g. atrial fibrillation) that could compromise the study or the safety of the subject.
• Clinically important infection within 30 days prior to screening e.g. chronic persistent or acute infection, such as bronchitis or urinary tract infection.
• Any known hypersensitivity to any of the excipients contained in the test article formulation.
• Severe hepatic failure (Child-Pugh C) OR kidney failure (creatinine clearance (eGFR) ≤ 30 ml/min/1.73m2) OR serum creatinine above 1.5 fold of ULN OR AST or ALT above 3 fold of ULN at screening.´
• Concomitant Medication/Therapies:
• The following therapies are not permitted for the given intervals prior to baseline and until End-of-treatment (EOT):
• Use of experimental medications for AD or any other investigational medications or devices for treatment of indications other than AD within 60 days prior to baseline.
• Treatment with Souvenaid, except if the use of Souvenaid was discontinued at least two months prior to baseline, or if the subject is on stable dose for at least six months prior to baseline and is willing to continue the use of Souvenaid during the study on the same dose and frequency.

Sponsors & Collaborators

• Vivoryon Therapeutics N.V.: lead
• Julius Clinical: collaborator
• Amsterdam UMC, location VUmc: collaborator

Study Sites (23)

Ziekenhuis Netwerk Antwerpen / Geheugenkliniek

Hoboken, 2660, Belgium

Location

Kliininen tutkimuskeskus

Kuopio, 70211, Finland

Location

Oulu University Hospital

Oulu, 90220, Finland

Location

CRST Oy

Turku, 20520, Finland

Location

CHU Bordeaux Pellegrin (CMRR)

Bordeaux, 33076, France

Location

CHU François Mitterand (Centre Mémoire Ressources Recherche (CMRR))

Dijon, 21079, France

Location

CHRU de Lille / Hôpital Roger Salengro

Lille, 59037, France

Location

Hôpital La Grave / Centre de Recherche Clinique

Toulouse, 31059, France

Location

Charité - Universitätsmedizin Berlin

Berlin, 10450, Germany

Location

Universitätsmedizin Göttingen / Klinik für Psychiatrie und Psychotherapie

Göttingen, 37075, Germany

Location

Universitätsklinikum Halle (Saale) Klinik und Poliklinik für Psychiatrie, Psychotherapie und Psychosomatik

Halle, 06112, Germany

Location

Arzneimittelforschung Leipzig GmbH

Leipzig, 04107, Germany

Location

Universitätsklinikum Magdeburg / Institut für Kognitive Neurologie und Demenzforschung

Magdeburg, 39120, Germany

Location

Klinikum rechts der Isar der TU München / Klinik für Psychiatrie und Psychotherapie

München, 81675, Germany

Location

Universitätsklinikum Münster / Klinik für Allgemeine Neurologie

Münster, 48149, Germany

Location

Universitätsmedizin Rostock / Zentrum für Nervenheilkunde/ Klinik für Psychosomatik und Psychotherapeutische Medizin

Rostock, 18147, Germany

Location

Neurologische Universitätsklinik Ulm

Ulm, 89081, Germany

Location

Alzheimer Research Center

Amsterdam, 1081 GM, Netherlands

Location

Hospital de la Santa Creu i Sant Pau, Neurology Department, Memory Unit

Barcelona, 08025, Spain

Location

Fundació ACE. Institut Català de Neurociències Aplicades

Barcelona, 08028, Spain

Location

Complexo Hospitalario Universitario de Santiago (CHUS)

Santiago de Compostela, 15706, Spain

Location

Hospital Universitario Virgen Macarena

Seville, 41009, Spain

Location

Verksamheten för neuropsykiatri Sahlgrenska universitetssjukhuset

Mölndal, 43141, Sweden

Location

Related Publications (1)

• Scheltens P, Hallikainen M, Grimmer T, Duning T, Gouw AA, Teunissen CE, Wink AM, Maruff P, Harrison J, van Baal CM, Bruins S, Lues I, Prins ND. Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase 2a study. Alzheimers Res Ther. 2018 Oct 12;10(1):107. doi: 10.1186/s13195-018-0431-6.

  PMID: 30309389 DERIVED

MeSH Terms

Conditions

Alzheimer Disease

Condition Hierarchy (Ancestors)

Dementia; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Tauopathies; Neurodegenerative Diseases; Neurocognitive Disorders; Mental Disorders

Study Officials

• Frank Weber, Dr.

  Vivoryon Therapeutics N.V.

  STUDY DIRECTOR

• Philip Scheltens, Prof. Dr.

  VUmc Alzheimer Centre (p: +31 20 4440816)

  STUDY CHAIR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 5, 2015
• First Posted: March 17, 2015
• Study Start: March 1, 2015
• Primary Completion: April 1, 2017
• Study Completion: April 1, 2017
• Last Updated: June 1, 2017

Record last verified: 2017-01

Locations

BE (1); FI (3); FR (4); DE (9); NL (1); ES (4); SE (1)